karppaus.infon arkistoitu foorumi

Weight and metabolic changes in early psychosis―association with daily quantification of medication exposure during the first hospitalization

First published: 01 August 2023
https://doi.org/10.1111/acps.13594


Abstract
Background

The most common causes of death in schizophrenia are cardiovascular disorders, which are closely related to metabolic syndrome/obesity. To better understand the development of metabolic alterations early in the course of illness, we quantified daily medication exposure in the first days of the first hospitalization for psychosis and related it to changes in weight and metabolic markers.

Study Design

We recruited participants with first episode psychosis (FEP, N = 173) during their first psychiatric hospitalization and compared them to controls (N = 204). We prospectively collected weight, body mass index, metabolic markers, and exact daily medication exposure at admission and during hospitalization.

Study Results

Individuals with FEP gained on average 0.97 ± 2.26 BMI points or 3.46 ± 7.81 kg of weight after an average of 44.6 days of their first inpatient treatment. Greater antipsychotic exposure was associated with greater BMI increase, but only in people with normal/low baseline BMI. Additional predictors of weight gain included type of medication and duration of treatment. Medication exposure was not directly related to metabolic markers, but higher BMI was associated with higher TGC, TSH, and lower HDL. Following inpatient treatment, participants with FEP had significantly higher BMI, TGC, prolactin, and lower fT4, HDL than controls.

Conclusion

During their first admission, people with FEP, especially those with normal/low baseline BMI, showed a rapid and clinically significant weight increase, which was associated with exposure to antipsychotics, and with metabolic changes consistent with metabolic syndrome. These findings emphasize weight monitoring in FEP and suggest a greater need for caution when prescribing metabolically problematic antipsychotics to people with lower BMI.

Significant outcomes
During their first inpatient treatment, individuals with FEP gained on average 0.97 ± 2.26 BMI points or 3.46 ± 7.81 kg of weight.
Low to normal baseline BMI was a significant predictor of greater weight gain following antipsychotic treatment. The weight gain in people with low to normal baseline BMI was clinically significant in almost half of them (45.9%) and resulted in early onset of metabolic abnormalities. Metabolic alterations (high TGC, low HDL) were more closely related to weight than to exposure to medications.